Once-daily indacaterol/glycopyrronium reduces the rate and risk of moderate or severe exacerbations compared with twice-daily salmeterol/fluticasone in a subset of gold froup D COPD patients with a history of >= 2 exacerbations or 1 hospitalization: the FLAME study - Vogelmeier, C; Wedzicha, J; Donohue, J; Fucile, S; Yadao, A; Ayers, T; Thach, C; FowlerTaylor, A; Fogel, R; Patalano, F; Banerji, D (Pneumologie, 2018)